Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.08
AIQ's Cash to Debt is ranked lower than
54% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. AIQ: 0.08 )
AIQ' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.08

Equity to Asset -0.36
AIQ's Equity to Asset is ranked lower than
54% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. AIQ: -0.36 )
AIQ' s 10-Year Equity to Asset Range
Min: -0.39   Max: 0.04
Current: -0.36

-0.39
0.04
F-Score: 6
Z-Score: 0.88
M-Score: -3.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 1.39
AIQ's Operating margin (%) is ranked higher than
73% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. AIQ: 1.39 )
AIQ' s 10-Year Operating margin (%) Range
Min: -39.88   Max: 26.28
Current: 1.39

-39.88
26.28
Net-margin (%) 1.07
AIQ's Net-margin (%) is ranked higher than
75% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. AIQ: 1.07 )
AIQ' s 10-Year Net-margin (%) Range
Min: -32.43   Max: 18.69
Current: 1.07

-32.43
18.69
ROA (%) 0.97
AIQ's ROA (%) is ranked higher than
76% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. AIQ: 0.97 )
AIQ' s 10-Year ROA (%) Range
Min: -21.65   Max: 5.34
Current: 0.97

-21.65
5.34
ROC (Joel Greenblatt) (%) 3.02
AIQ's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. AIQ: 3.02 )
AIQ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -63.3   Max: 29.52
Current: 3.02

-63.3
29.52
Revenue Growth (3Y)(%) -2.40
AIQ's Revenue Growth (3Y)(%) is ranked higher than
67% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. AIQ: -2.40 )
AIQ' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2.8   Max: 27
Current: -2.4

-2.8
27
EBITDA Growth (3Y)(%) -4.40
AIQ's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. AIQ: -4.40 )
AIQ' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -20.5   Max: 151.9
Current: -4.4

-20.5
151.9
EPS Growth (3Y)(%) -13.20
AIQ's EPS Growth (3Y)(%) is ranked higher than
67% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. AIQ: -13.20 )
AIQ' s 10-Year EPS Growth (3Y)(%) Range
Min: -70   Max: 122.4
Current: -13.2

-70
122.4
» AIQ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

AIQ Guru Trades in Q4 2013

Jim Simons 442,560 sh (+2.17%)
Howard Marks 4,756,490 sh (unchged)
» More
Q1 2014

AIQ Guru Trades in Q1 2014

Jim Simons 499,159 sh (+12.79%)
Howard Marks 4,756,490 sh (unchged)
» More
Q2 2014

AIQ Guru Trades in Q2 2014

Jim Simons 566,160 sh (+13.42%)
Howard Marks 4,756,491 sh (unchged)
» More
Q3 2014

AIQ Guru Trades in Q3 2014

Jim Simons 592,260 sh (+4.61%)
Howard Marks 4,756,491 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AIQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 49.70
AIQ's P/E(ttm) is ranked higher than
81% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. AIQ: 49.70 )
AIQ' s 10-Year P/E(ttm) Range
Min: 10.21   Max: 868.06
Current: 49.7

10.21
868.06
P/S 0.53
AIQ's P/S is ranked higher than
96% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.17 vs. AIQ: 0.53 )
AIQ' s 10-Year P/S Range
Min: 0.08   Max: 1.54
Current: 0.53

0.08
1.54
PFCF 3.92
AIQ's PFCF is ranked higher than
99% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. AIQ: 3.92 )
AIQ' s 10-Year PFCF Range
Min: 0.74   Max: 28.19
Current: 3.92

0.74
28.19
EV-to-EBIT 121.53
AIQ's EV-to-EBIT is ranked higher than
74% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. AIQ: 121.53 )
AIQ' s 10-Year EV-to-EBIT Range
Min: -395.9   Max: 356.7
Current: 121.53

-395.9
356.7
Current Ratio 1.86
AIQ's Current Ratio is ranked higher than
62% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. AIQ: 1.86 )
AIQ' s 10-Year Current Ratio Range
Min: 1   Max: 2.87
Current: 1.86

1
2.87
Quick Ratio 1.86
AIQ's Quick Ratio is ranked higher than
66% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. AIQ: 1.86 )
AIQ' s 10-Year Quick Ratio Range
Min: 1   Max: 2.87
Current: 1.86

1
2.87

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.80
AIQ's Price/DCF (Projected) is ranked higher than
99% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. AIQ: 0.80 )
AIQ' s 10-Year Price/DCF (Projected) Range
Min: 0.17   Max: 5
Current: 0.8

0.17
5
Price/Median PS Value 0.82
AIQ's Price/Median PS Value is ranked higher than
91% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. AIQ: 0.82 )
AIQ' s 10-Year Price/Median PS Value Range
Min: 0.17   Max: 3.25
Current: 0.82

0.17
3.25
Earnings Yield (Greenblatt) 0.80
AIQ's Earnings Yield (Greenblatt) is ranked higher than
73% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. AIQ: 0.80 )
AIQ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 11.7
Current: 0.8

0.3
11.7
Forward Rate of Return (Yacktman) 18.03
AIQ's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.28 vs. AIQ: 18.03 )
AIQ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 5   Max: 148.5
Current: 18.03

5
148.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AI6M.Germany,
Its diagnostic imaging services include magnetic resonance imaging technology and positron emission tomography/computed tomography services that generate representations of the internal anatomy and convert them to film or digital media. The Company operates in two reportable segments, Imaging and Radiation Oncology. It offers non scan-based services, which comprise the use of imaging systems under a short-term contract. In addition, it provides radiation oncology services that include conventional beam therapy, 3-D conformal radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, stereotactic radiosurgery, low dose rate brachytherapy, and high dose rate brachytherapy for the treatment of cancer; and stereotactic radiation oncology services. Further, the Company offers ancillary services, such as marketing support, education, training, and billing assistance. It provides imaging and therapeutic services through hospitals and clinics, independent imaging and radiation oncology centers, and other healthcare providers on a shared-service and full-time service basis, as well as provides services through fixed-sites, primarily to hospitals or health systems. It competes with RadNet, Inc., Center for Diagnostic Imaging. The Company is subject to federal and state government regulations. It is also subject to various environmental, health, and safety laws regulated by the government.
» More Articles for AIQ

Headlines

Articles On GuruFocus.com
comment on AIQ Aug 20 2011 
Alliance Imaging Inc. Reports Operating Results (10-K) Mar 14 2011 
Alliance Imaging Inc. Reports Operating Results (10-Q) Nov 05 2010 
Alliance Imaging Inc. (AIQ) CEO Paul S Viviano buys 10,000 Shares Aug 09 2010 
Alliance Imaging Announces Acquisition of Shared P.E.T. Imaging, LLC Dec 16 2008 
Alliance Imaging Schedules Conference Call and Webcast to Review Full Year 2009 Financial Guidance Dec 12 2008 

More From Other Websites
ALLIANCE HEALTHCARE SERVICES, INC Financials Nov 15 2014
10-Q for Alliance HealthCare Services, Inc. Nov 10 2014
Charleston Area Medical Center and Alliance Oncology Receive State Approval for New Radiation... Nov 10 2014
Charleston Area Medical Center and Alliance Oncology Receive State Approval for New Radiation... Nov 10 2014
ALLIANCE HEALTHCARE SERVICES, INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 07 2014
Alliance HealthCare Services Inc Earnings Call scheduled for 5:00 pm ET today Nov 06 2014
Alliance HealthCare Services Reports Results for Third Quarter 2014 Nov 06 2014
Q3 2014 Alliance HealthCare Services Inc Earnings Release - After Market Close Nov 06 2014
Alliance HealthCare Services Schedules Conference Call and Webcast to Review Third Quarter 2014... Oct 30 2014
Alliance HealthCare Services Schedules Conference Call and Webcast to Review Third Quarter 2014... Oct 30 2014
Charleston Area Medical Center and Alliance Oncology Set to Establish a New Radiation Therapy... Sep 09 2014
ALLIANCE HEALTHCARE SERVICES, INC Files SEC form 8-K, Regulation FD Disclosure Sep 08 2014
Why Alliance HealthCare (AIQ) Stock Is Higher Today Sep 05 2014
ALLIANCE HEALTHCARE SERVICES, INC Files SEC form 10-Q, Quarterly Report Aug 08 2014
Alliance HealthCare Services Reports Results for Second Quarter 2014 Aug 07 2014
ALLIANCE HEALTHCARE SERVICES, INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 07 2014
Alliance Healthcare Services Schedules Conference Call and Webcast to Review Second Quarter 2014... Jul 31 2014
Alliance HealthCare Services Inc Stock Upgraded (AIQ) Jun 11 2014
ALLIANCE HEALTHCARE SERVICES, INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 09 2014
Alliance HealthCare Services Receives Avatar’s Exceeding Patient Expectations Award Seventh Year... May 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK